Iradimed Co Stock Current Valuation
| IRMD Stock | USD 60.33 1.16 1.96% |
Valuation analysis of Iradimed helps investors to measure Iradimed's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The current year's Enterprise Value is expected to grow to about 520.3 M, whereas Enterprise Value Over EBITDA is forecasted to decline to 22.63. Fundamental drivers impacting Iradimed's valuation include:
Undervalued
Today
Please note that Iradimed's price fluctuation is very steady at this time. Calculation of the real value of Iradimed is based on 3 months time horizon. Increasing Iradimed's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Iradimed stock is determined by what a typical buyer is willing to pay for full or partial control of Iradimed Co. Since Iradimed is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Iradimed Stock. However, Iradimed's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 60.33 | Real 65.93 | Target 65.0 | Hype 59.54 |
The real value of Iradimed Stock, also known as its intrinsic value, is the underlying worth of Iradimed Company, which is reflected in its stock price. It is based on Iradimed's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Iradimed's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Iradimed Co helps investors to forecast how Iradimed stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Iradimed more accurately as focusing exclusively on Iradimed's fundamentals will not take into account other important factors: Iradimed Co Company Current Valuation Analysis
Iradimed's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Iradimed Current Valuation | 698.43 M |
Most of Iradimed's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Iradimed Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Iradimed Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Iradimed is extremely important. It helps to project a fair market value of Iradimed Stock properly, considering its historical fundamentals such as Current Valuation. Since Iradimed's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Iradimed's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Iradimed's interrelated accounts and indicators.
Click cells to compare fundamentals
Iradimed Current Valuation Historical Pattern
Today, most investors in Iradimed Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Iradimed's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Iradimed current valuation as a starting point in their analysis.
Iradimed Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Iradimed Co has a Current Valuation of 698.43 M. This is 95.14% lower than that of the Health Care Equipment & Supplies sector and 94.38% lower than that of the Health Care industry. The current valuation for all United States stocks is 95.8% higher than that of the company.
Iradimed Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Iradimed's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Iradimed could also be used in its relative valuation, which is a method of valuing Iradimed by comparing valuation metrics of similar companies.Iradimed is currently under evaluation in current valuation category among its peers.
Iradimed Current Valuation Drivers
We derive many important indicators used in calculating different scores of Iradimed from analyzing Iradimed's financial statements. These drivers represent accounts that assess Iradimed's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Iradimed's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 276.4M | 570.5M | 355.4M | 598.3M | 538.4M | 565.4M | |
| Enterprise Value | 229.1M | 511.0M | 299.6M | 550.5M | 495.5M | 520.3M |
Iradimed ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Iradimed's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Iradimed's managers, analysts, and investors.Environmental | Governance | Social |
Iradimed Fundamentals
| Return On Equity | 0.24 | ||||
| Return On Asset | 0.15 | ||||
| Profit Margin | 0.26 % | ||||
| Operating Margin | 0.32 % | ||||
| Current Valuation | 698.43 M | ||||
| Shares Outstanding | 12.67 M | ||||
| Shares Owned By Insiders | 37.05 % | ||||
| Shares Owned By Institutions | 57.19 % | ||||
| Number Of Shares Shorted | 124.05 K | ||||
| Price To Earning | 28.70 X | ||||
| Price To Book | 8.99 X | ||||
| Price To Sales | 10.52 X | ||||
| Revenue | 65.56 M | ||||
| Gross Profit | 55 M | ||||
| EBITDA | 20.04 M | ||||
| Net Income | 17.19 M | ||||
| Cash And Equivalents | 55.59 M | ||||
| Cash Per Share | 4.42 X | ||||
| Total Debt | 2.04 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 12.83 X | ||||
| Book Value Per Share | 6.58 X | ||||
| Cash Flow From Operations | 13.47 M | ||||
| Short Ratio | 2.79 X | ||||
| Earnings Per Share | 1.46 X | ||||
| Price To Earnings To Growth | 4.46 X | ||||
| Target Price | 65.0 | ||||
| Number Of Employees | 148 | ||||
| Beta | 0.8 | ||||
| Market Capitalization | 749.89 M | ||||
| Total Asset | 92.16 M | ||||
| Retained Earnings | 43.26 M | ||||
| Working Capital | 59.67 M | ||||
| Current Asset | 33.95 M | ||||
| Current Liabilities | 2.89 M | ||||
| Annual Yield | 0.01 % | ||||
| Net Asset | 92.16 M | ||||
| Last Dividend Paid | 0.45 |
About Iradimed Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Iradimed Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Iradimed using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Iradimed Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Iradimed is a strong investment it is important to analyze Iradimed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Iradimed's future performance. For an informed investment choice regarding Iradimed Stock, refer to the following important reports:Check out Iradimed Piotroski F Score and Iradimed Altman Z Score analysis. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iradimed. If investors know Iradimed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iradimed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0) | Dividend Share 0.45 | Earnings Share 1.46 | Revenue Per Share | Quarterly Revenue Growth 0.11 |
The market value of Iradimed is measured differently than its book value, which is the value of Iradimed that is recorded on the company's balance sheet. Investors also form their own opinion of Iradimed's value that differs from its market value or its book value, called intrinsic value, which is Iradimed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iradimed's market value can be influenced by many factors that don't directly affect Iradimed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iradimed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Iradimed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iradimed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.